Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin For patients with STEMI undergoing primary PCI.

Slides:



Advertisements
Similar presentations
A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Advertisements

Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Stone p2203/Abstract/ Conclusions
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.
Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights.
Safety and Effectiveness of Bivalirudin in NSTE ACS by duration of the upstream infusion in the ACUITY trial: Implications for ED and upstream management.
Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,
Bivalirudin with Provisional GPIIb/IIIa Inhibition – the Data are Clear! Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Pharmacological strategies to reduce periprocedural bleeding
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl, Frederick Feit, Antonio.
Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.
Dr Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield UK Managing bleeding post PCI.
Gregg W. Stone, Tim Clayton, Roxana Mehran, Efthymios N. Deliargyris, Jayne Prats, Stuart J. Pocock TCT 2012; JACC 2012;60(17SupplB):B16 The HORIZONS-AMI.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
TCT 2009 Stent Thrombosis Following Primary PCI in STEMI: Predictors, Clinical Impact and Preventive Strategies from the Horizons AMI Trial George D. Dangas,
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Switch Switch Safety and Efficacy of Crossover (Switch) from UFH/Enox to Bivalirudin: Results from ACUITY Dr. Harvey White Green Lane Cardiovascular Service.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Gregg W. Stone, Tim Clayton, Roxana Mehran, Efthymios N. Deliargyris, Jayne Prats, Stuart J. Pocock Bivalirudin Reduces Cardiac Mortality in Patients with.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
比伐卢定在 STEMI 中的应用价值 王乐丰 首都医科大学附属北京朝阳医院心脏中心. Goals of STEMI PCI Establish reperfusion of IRA ASAP Limit complications Limit costs Achieve excellent long.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Meta Analysis of Primary PCI trials Andreas Baumbach*, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran,
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing.
Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin Advancing Anticoagulation in ACS.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Intra-procedural Anticoagulation for PCI: Which Drug? How Much? How Long? Michael J. Cowley, FSCAI Nothing to Disclose.
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
AHA 2011 Late Breaking Trials Synthesis and Critical Review.
Northeast Georgia Heart Center Interventional Pharmacology: Anti-thrombin Therapy J. Jeffrey Marshall, MD, FSCAI Past President SCAI, Director.
Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
Heparin Should be the First-line Therapy for Patients with ACS/AMI
For the HORIZONS-AMI Investigators
Bivalirudin is Superior to Heparin for ACS Patients
For the HORIZONS-AMI Investigators
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
DES Should be Used as the Default Stent in ACS!
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
Dr. Harvey White on behalf of the ACUITY investigators
How and why this study may change my practice ?
The HORIZONS-AMI Trial
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
ARNO TRIAL (Antithrombotic Regimens aNd Outcome)
% Heparin + GPI IIb/IIIa Bivalirudin +
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
on behalf of the ACUITY investigators
What oral antiplatelet therapy would you choose?
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
The following slides are highlights of a report based on a TCTMD Webcast Scientific Presentation on February 19, 2003 that was originally presented by.
Presentation transcript:

Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin For patients with STEMI undergoing primary PCI

MY CONFLICTS OF INTEREST ARE The Medicines Company (Employee)

New Indication for STEMI –Approved in the European Union in 2004 As an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) –Type II variation approved in 2008 For the treatment of patients with ACS undergoing early or urgent intervention –Type II variation approved in 2009 As an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including primary PCI “The only anticoagulant approved for patients undergoing PPCI”

Broad spectrum of experience with bivalirudin in clinical trials 27,735 patients undergoing invasive management of CAD REPLACE-2 (N=6,002) CAD Planned PCI BAT (N=4,312) UA, NQWMI Planned PTCA ACUITY (N=13,819) NSTE-ACS PCI <72h HORIZONS (N=3,602) STEMI Emergency PCI Increasing risk of ischaemic complications Lincoff et al JAMA, 2003 Bittl et al AHJ, 2001 Stone et al NEJM, 2006 Stone et al NEJM, 2007

Consistent trial results ● Meta-analysis of REPLACE-2, ACUITY and HORIZONS ● 14,258 patients given aspirin, clopidogrel prior to angio/intervention Risk ratio ±95% CIP-value Death, MI or revasc 30d1.0 ( )0.941 All cause death 30d0.73 ( )0.043 All cause death 1y0.80 ( )0.015 Major bleeding 30d0.54 ( )< Bivalirudin betterHeparin+GPI better Data on file The Medicines Company Mehran ESC 2009

● The data source for the analysis is the Premier Perspective Database ● A total of 127,185 PCI procedures were identified from the database between June 2003 through December 2006 ● Patients received either bivalirudin plus provisional GPI or the comparator, heparin plus GPIIb/IIIa Rassen JA et al Eur Heart J 2009 PREMIER Dataset

Hazard Ratio ± 95% CI OR (95% CI) Fully adjusted HR for transfusion0.67 (0.61–0.73) Fully adjusted HR for repeat PCI0.96 (0.90–1.03) Fully adjusted HR for death0.51 (0.44–0.60) Bivalirudin Better Heparin + GP IIb/IIIa Inhibitor Better 7 ANGIOX is Effective in Routine Care ● Angiox reduced the risk of in-hospital death and blood transfusions Rassen JA et al Eur Heart J 2009

Primary PCI Strategy Aspirin, thienopyridine 3,000 pts eligible for stent randomisation Bare metal stentpaclitaxel-eluting stent Clinical FU at 30 days, 1 yr, 2 years HORIZONS AMI Trial Design ● Open-label, randomised, prospective, multicenter trial FU=follow-up; pts=patients; R=randomised; UFH=unfractionated heparin. Stone GW. NEJM 2008;358: UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) Bivalirudin monotherapy (± provisional GP IIb/IIIa) 3,602 pts with STEMI with symptom onset ≤12 hours R 1:3 R 1:1 8

30-day Clinical Outcomes 30-day event rates (%) NACEMajor Bleeding † MACE ‡ *In HORIZONS AMI, 93% of bivalirudin patients received monotherapy, without provisional GP IIb/IIIa. †Not related to CABG. ‡MACE=all-cause death, reinfarction, ischaemic TVR, or stroke. Stone GW. NEJM 2008;358: : 9 Diff = 0.0% [-1.6, 1.5] RR = 0.99 [0.76, 1.30] P sup = 0.95 Diff = -3.3% [-5.0, -1.6] RR = 0.60 [0.46, 0.77] P NI ≤ P sup ≤ Diff = -2.9% [-4.9, -0.8] RR = 0.76 [0.63, 0.92] P NI ≤ P sup = 0.005

30-day MACE Components 10 Bivalirudin (n=1,800)* UFH + GP IIb/IIIa (n=1,802)P value Mortality † 2.1%3.1% Cardiac1.8%2.9% Noncardiac0.3%0.2%0.75 Reinfarction1.8% Q-wave1.4%1.2% Non–Q-wave0.4%0.7%0.37 Ischaemic TVR2.6%1.9%0.18 Stroke0.7%0.6%0.68 *In HORisONS AMI, 93% of bivalirudin patients received monotherapy, without provisional GP IIb/IIIa. †Adjudicated. TLR=target lesion revascularisation. Stone GW. NEJM 2008;358:

2-Year Reinfarction p= HR [95%CI]= 0.75 [0.56, 0.98] 5.1% 6.9% Reinfarction (%) Number at risk Bivalirudin alone Heparin+GPIIb/IIIa Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) Months Stone GW TCT 2009

HORIZONS 2 year follow-up ● Cardiac mortality in ITT population ↓41%* 2.5% 4.2% Months Cardiac mortality (%) 2.1% 3.7 % ↓43%* 1.8% 2.9% ↓38%* All p≤0.03 *Relative risk reduction BivalirudinUFH+GPI Stone et al TCT 2009

HORIZONS Stent thrombosis

30 Day Stent Thrombosis (N=3,124) UFH + GP IIb/IIIa (N=1553) Bivalirudin (N=1571) P Value ARC definite or probable* 1.9%2.5% definite 1.4%2.2% probable 0.5%0.3% acute (≤24 hrs) 0.3%1.3% subacute (>24 hrs – 30d) 1.7%1.2%0.30 *Protocol definition of stent thrombosis, CEC adjudicated

HORIZONS ST to 30 days ● Increase in acute ST offset by decrease in sub-acute ST BivalirudinUFH+GPI Estimated event rate (%) Days from randomisation acute ST 4 acute ST 30 sub-acute ST 20 sub-acute ST Stone et al NEJM, 2008

GPIIb/IIIa and stent thrombosis ● Cumulative distribution for time to development of ST according to GPIIb-IIIa inhibitor exposure. Among patients who received GPIIb-IIIa blockade, the median time to development of ST was increased from 2 to 5 days (P =.002) Cumulative Frequency of ST Days No GP IIb/IIIa Pretreatment GP IIb/IIIa Pretreatment P =.002 Rinaldi Am Heart J 2008;155:654-60

Timing of Stent Thrombosis in Patients Treated with Tirofiban. Assali AR J Invasive Cardiol Sep;12(9):460-3 Retrospective analysis of a single-center intervention database between January1997 and October patients identified with acute or subacute stent thrombosis The median time from stent deployment to ST was 7 hours (IQR, hours) in patients not receiving a GPIIb/IIIa antagonist compared to 84.5 hours (IQR, hours) in patients receiving one.

18 ST TypeBivalirudin (N=1800) UFH + GPI (N=1802) Risk of death (n/N [%]) STDeathSTDeath Acute231412/27 (7.4) Subacute /49 (34.7) 30 Day Stent Thrombosis – Risk of Subsequent Death

Deaths at 1 year subsequent to major events Number of deaths Major eventBivalirudin UFH + GP IIb/IIIa TotalDelta Acute ST1120 Subacute ST Late ST3693 Major Bleeding Re-Infarction Stroke5491

HORIZONS Review Did the dose of clopidogrel impact outcomes?

Clopidogrel 300mg versus 600mg 21 The impact of bivalirudin was independent of the clopidogrel loading dose. Interaction P values = 0.48 (NACE) 0.41 (Major bleeding), and 0.75 (MACE). Significant decrease in MACE in patients treated with 600mg versus 300mg clopidogrel MACE at 30 days Clopidogrel 300mgClopidogrel 600mg P-value Bivalirudin 43/595 (7.2) 46/1125 (4.1) UFH + GP IIb/IIIa43/618 (7.0)48/1091 (4.4) Dangas et al, JACC 2009

Clopidogrel and Stent Thrombosis 22

Optimising outcomes with bivalirudin ● Early adjunctive therapy Early adjunctive therapy with guideline recommended therapies (which should include aspirin and clopidogrel and may include UFH) was associated with a reduced rate of AST in both arms of HORIZONS ● Adequate PY12 inhibition Treatment with Clopidogrel 600 mg vs. 300mg resulted in improved MACE in both arms Prasugrel 60 mg may be better than clopidogrel ● Prolonged bivalirudin infusion A post PCI infusion of bivalirudin at 0.25/mg/kg infusion for up to 4 hours does not increase bleeding (BAT) and does not affect sheath pull times (AFRICA) Prolonged antithrombin therapy until such time that P2Y12 inhibition is effective may further reduce AST 23

Krumholz,. et al. JAMA 2009;302: Trends in 30d mortality after AMI ● All-Cause risk-standardised mortality

Conclusion ● In HORIZONS-AMI the significant reductions in cardiac- related death at 30-days, 1-year and 2-years are important. ● For every 59 patients with STEMI undergoing primary PCI with bivalirudin compared to conventional therapies one cardiac related death might be avoided (NNT= 59 at 1 yr). ● The important implications of the HORIZONS study are now reflected in the recently updated ACC/AHA guidelines for the management of patients with STEMI undergoing primary PCI where bivalirudin received a (Class IB) recommendation [Kushner et al., 2009]. ● In conclusion, the favourable risk–benefit profile of bivalirudin, make it clinically important alternative to current treatments for the contemporary management of STEMI patients undergoing primary PCI.